Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus.

BACKGROUND Visfatin and adiponectin are produced by adipose tissue and have opposite effects on insulin resistance. Circulating concentrations of these biomarkers are altered in type 2 diabetes mellitus. We sought to examine the potential value of maternal serum visfatin and adiponectin concentrations in early pregnancy as potential biomarkers in the prediction of gestational diabetes mellitus (GDM). METHODS This work was a case-control study of 100 women who developed GDM and 300 nondiabetic controls. Maternal serum visfatin and adiponectin were measured between 11 and 13 weeks of gestation. Regression analysis in the nondiabetic group was performed to examine the maternal characteristics affecting the serum concentrations of visfatin and adiponectin. Likelihood ratios for GDM were calculated for visfatin and adiponectin, and performance of screening was assessed by using ROC curve analysis. RESULTS In the GDM group compared with the nondiabetic group, the median maternal serum visfatin concentration was increased (1.34 multiples of the median [MoM], interquartile range [IQR] 0.70-2.87, vs 1.00 MoM, IQR: 0.53-1.92; P = 0.004) and serum adiponectin was decreased (0.66 MoM, IQR 0.50-0.92, vs 1.01, IQR 0.70-1.29; P < 0.0001). In screening for GDM by a combination of maternal factors and serum adiponectin and visfatin, the estimated detection rate was 68.0% (95% CI 58.3-76.3%), at a false-positive rate of 10%. CONCLUSIONS At 11-13 weeks in pregnancies that develop GDM, the serum concentration of adiponectin is decreased and visfatin is increased, and these biomarkers can be combined with maternal factors to provide effective early screening for GDM.

[1]  B. Zinman,et al.  Decreased high‐molecular‐weight adiponectin in gestational diabetes: implications for the pathophysiology of Type 2 diabetes , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[2]  T. Ozgurtas,et al.  The role of visfatin in the pathogenesis of gestational diabetes mellitus. , 2011, Journal of endocrinological investigation.

[3]  G. Rice,et al.  Screening for biomarkers predictive of gestational diabetes mellitus , 2008, Acta Diabetologica.

[4]  E. A. Sims,et al.  Longitudinal changes in insulin release and insulin resistance in nonobese pregnant women. , 1991, American journal of obstetrics and gynecology.

[5]  M. Kılınç,et al.  Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus , 2010, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[6]  Surabhi Nanda,et al.  Prediction of gestational diabetes mellitus by maternal factors and biomarkers at 11 to 13 weeks , 2011, Prenatal diagnosis.

[7]  Chun-Hsien Yu,et al.  Maternal plasma adiponectin concentrations at 24 to 31 weeks of gestation: negative association with gestational diabetes mellitus. , 2005, Nutrition.

[8]  M. Górska,et al.  Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue. , 2009, Diabetes research and clinical practice.

[9]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[10]  S. Amini,et al.  Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. , 1999, American journal of obstetrics and gynecology.

[11]  Xiaotian Li,et al.  The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. , 2010, Diabetes research and clinical practice.

[12]  H. Randeva,et al.  Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance , 2007, Diabetologia.

[13]  R. Romero,et al.  Maternal serum adiponectin multimers in gestational diabetes , 2009, Journal of perinatal medicine.

[14]  P. Catalano,et al.  Metabolic changes in pregnancy. , 2007, Clinical obstetrics and gynecology.

[15]  Shyi-Jang Shin,et al.  Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. , 2006, The Journal of clinical endocrinology and metabolism.

[16]  G. La Torre,et al.  Longitudinal changes of adiponectin, carbohydrate and lipid metabolism in pregnant women at high risk for gestational diabetes , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[17]  K. Nicolaides.  A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment , 2011, Prenatal diagnosis.

[18]  K. Kagan,et al.  Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A , 2008, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[19]  I. Papassotiriou,et al.  The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity. , 2007, Clinical chemistry.

[20]  D. Luthy,et al.  Plasma adiponectin concentrations in early pregnancy and subsequent risk of gestational diabetes mellitus. , 2003, The Journal of clinical endocrinology and metabolism.

[21]  B. Zinman,et al.  Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications , 2005, Diabetologia.

[22]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[23]  A. Malamitsi‐Puchner,et al.  Reviews: Adipocytokines in Normal and Complicated Pregnancies , 2009, Reproductive Sciences.

[24]  R. Ness,et al.  First trimester adipocytokine concentrations and risk of developing gestational diabetes later in pregnancy , 2008, Clinical endocrinology.

[25]  E. Sivan,et al.  Adiponectin and human pregnancy , 2005, Current Diabetes Reports.

[26]  R. Romero,et al.  Visfatin in human pregnancy: maternal gestational diabetes vis-à-vis neonatal birthweight , 2008, Journal of perinatal medicine.

[27]  A. Altinova,et al.  Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester , 2008, Journal of endocrinological investigation.

[28]  David A. Miller,et al.  Perinatal survival following preferential sequential selective laser surgery for twin-twin transfusion syndrome , 2009, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[29]  G. Schernthaner,et al.  Increased visfatin concentrations in women with gestational diabetes mellitus. , 2006, Clinical science.

[30]  K. Nicolaides,et al.  UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation , 1998, The Lancet.

[31]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .